Dronabinol is under clinical development by IGC Pharma and currently in Phase II for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase II drugs for Dementia Associated With Alzheimer’s Disease have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dronabinol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IGC-AD1 (tetrahydrocannabinol) is under development for the treatment of mild to moderate dementia due to Alzheimer's disease. The drug candidate is a cannabinoid that acts by targeting glycogen synthase kinase-3 beta (GSK3b). It is administered through oral or sublingual route.
IGC Pharma overview
IGC Pharma focuses on cannabinoid research and the development of hemp-based pharmaceuticals and wellness solutions. IGC Pharma is headquartered in Potomac, Maryland, the US.
For a complete picture of Dronabinol’s drug-specific PTSR and LoA scores, buy the report here.